Stroke Warning Information and Faster Treatment (SWIFT): Cost-Effectiveness of a Stroke Preparedness Intervention

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.06.003
https://www.valueinhealthjournal.com/article/S1098-3015(19)32244-2/fulltext
Section Title : ECONOMIC EVALUATION
Section Order : 1240
First Page : 1240

Background

Less than 25% of stroke patients arrive to an emergency department within the 3-hour treatment window.

Objective

We evaluated the cost-effectiveness of a stroke preparedness behavioral intervention study (Stroke Warning Information and Faster Treatment [SWIFT]), a stroke intervention demonstrating capacity to decrease race-ethnic disparities in ED arrival times.

Methods

Using the literature and SWIFT outcomes for 2 interventions, enhanced educational (EE) materials, and interactive intervention (II), we assess the cost-effectiveness of SWIFT in 2 ways: (1) Markov model, and (2) cost-to-outcome ratio. The Markov model primary outcome was the cost per quality-adjusted life-year (QALY) gained using the cost-effectiveness threshold of $100 000/QALY. The primary cost-to-outcome endpoint was cost per additional patient with ED arrival 3 hours, stroke knowledge, and preparedness capacity. We assessed the ICER of II and EE versus standard care (SC) from a health sector and societal perspective using 2015 USD, a time horizon of 5 years, and a discount rate of 3%.

Results

The cost-effectiveness of the II and EE programs was, respectively, $227.35 and $74.63 per additional arrival 3 hours, $440.72 and $334.09 per additional person with stroke knowledge proficiency, and $655.70 and $811.77 per additional person with preparedness capacity. Using a societal perspective, the ICER for EE versus SC was $84 643 per QALY gained and the ICER for II versus EE was $59 058 per QALY gained. Incorporating fixed costs, EE and II would need to administered to 507 and 1693 or more patients, respectively, to achieve an ICER of $100 000/QALY.

Conclusion

II was a cost-effective strategy compared with both EE and SC. Nevertheless, high initial fixed costs associated with II may limit its cost-effectiveness in settings with smaller patient populations.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32244-2&doi=10.1016/j.jval.2019.06.003
HEOR Topics :
  • Cost/Cost of Illness/Resource Use Studies
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Economic Evaluation
  • Patient Behavior and Incentives
  • Patient-Centered Research
  • Patient-reported Outcomes & Quality of Life Outcomes
Tags :
  • acute stroke
  • cost-effectiveness
  • health literacy
  • patient education
  • patient-centered outcomes research
  • preparedness
Regions :